Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$1.46
+2.8%		$1.86
$0.96
▼
$2.98
$159.89M2.521.54 million shs757,823 shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$4.70
$4.55
$3.28
▼
$6.18
$610.91M1.18998,160 shs478,226 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$6.95
$8.18
$5.37
▼
$17.58
$468.01M1.761.17 million shs656,001 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.35
+3.8%		$1.41
$1.07
▼
$2.73
$419.62M2.316.67 million shs2.76 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-3.73%-14.46%-0.70%-44.53%-41.08%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
+0.21%+1.73%+9.81%+14.91%+19.29%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-1.76%-4.87%-26.09%-15.13%-38.86%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-1.52%-16.13%-9.72%-10.34%+3.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$1.46
+2.8%		$1.86
$0.96
▼
$2.98
$159.89M2.521.54 million shs757,823 shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$4.70
$4.55
$3.28
▼
$6.18
$610.91M1.18998,160 shs478,226 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$6.95
$8.18
$5.37
▼
$17.58
$468.01M1.761.17 million shs656,001 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.35
+3.8%		$1.41
$1.07
▼
$2.73
$419.62M2.316.67 million shs2.76 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-3.73%-14.46%-0.70%-44.53%-41.08%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
+0.21%+1.73%+9.81%+14.91%+19.29%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-1.76%-4.87%-26.09%-15.13%-38.86%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-1.52%-16.13%-9.72%-10.34%+3.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Codexis, Inc. stock logo
CDXS
Codexis
2.25
Hold$6.50345.21% Upside
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.33
Hold$5.5618.35% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.50
Reduce$7.000.72% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.80
Reduce$1.8335.80% Upside

Current Analyst Ratings Breakdown

Latest CDXS, CTKB, DNA, and PACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell$5.00
9/2/2026
Codexis, Inc. stock logo
CDXS
Codexis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/20/2026
Codexis, Inc. stock logo
CDXS
Codexis
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/17/2026
Codexis, Inc. stock logo
CDXS
Codexis
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$9.00 ➝ $8.00
8/17/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/11/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/7/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
8/7/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$12.00 ➝ $9.00
7/20/2026
Codexis, Inc. stock logo
CDXS
Codexis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Codexis, Inc. stock logo
CDXS
Codexis
$70.39M2.27N/AN/A$0.30 per share4.87
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$201.49M3.03N/AN/A$2.48 per share1.90
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M2.75N/AN/A$6.24 per share1.11
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$160.01M2.62$0.81 per share1.67($0.11) per share-12.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Codexis, Inc. stock logo
CDXS
Codexis
-$43.97M-$0.34N/AN/AN/A-39.55%-74.36%-23.58%11/5/2026 (Estimated)
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$66.54M-$0.62N/AN/AN/A-38.98%-12.40%-9.17%11/4/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.01N/AN/AN/A-259.96%-60.27%-26.88%11/5/2026 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$546.38M-$0.43N/AN/AN/A-82.49%-5,752.12%-19.52%11/3/2026 (Estimated)

Latest CDXS, CTKB, DNA, and PACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Codexis, Inc. stock logo
CDXS
Codexis
-$0.1417-$0.13+$0.0117-$0.13$13.82 million$14.92 million
8/5/2026Q2 2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.0933-$0.09+$0.0033-$0.09$47.31 million$48.14 million
8/5/2026Q2 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.8950-$0.75+$0.1450-$0.75$24.05 million$20.16 million
8/3/2026Q2 2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.1280-$0.14-$0.0120-$0.14$42.90 million$39.01 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Codexis, Inc. stock logo
CDXS
Codexis
1.03
3.06
2.99
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
4.48
3.86
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.57
4.57
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
4.92
4.03

Institutional Ownership

CompanyInstitutional Ownership
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A

Insider Ownership

CompanyInsider Ownership
Codexis, Inc. stock logo
CDXS
Codexis
3.50%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
10.36%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Codexis, Inc. stock logo
CDXS
Codexis
250109.51 million105.67 millionOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500129.98 million116.52 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64067.34 million58.80 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730310.83 million299.33 millionOptionable

Recent News About These Companies

Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
 |  zacks.comhttps://www.zacks.com/stock/news/2985290/pacific-biosciences-pacb-up-11-6-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2985290
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
September 3 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356242/16261/en/pacbio-to-participate-in-the-morgan-stanley-24%e1%b5%97%ca%b0-annual-global-healthcare-conference.html
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
September 2 at 2:56 PM  |  zacks.comhttps://www.zacks.com/stock/news/2984020/pacb-cuts-2026-outlook-as-clinical-adoption-faces-its-crucial-test?cid=cs-stocknewsapi-ft-analyst_blog_plus|zer_report_insights-2984020
BlackRock Inc. Buys Shares of 32,339,550 Pacific Biosciences of California, Inc. $PACB
September 1 at 3:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-buys-shares-of-32339550-pacific-biosciences-of-california-inc-pacb-2026-09-01/
Hhlr Advisors LTD. Acquires Shares of 918,892 Pacific Biosciences of California, Inc. $PACB
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hhlr-advisors-ltd-acquires-shares-of-918892-pacific-biosciences-of-california-inc-pacb-2026-08-27/
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) Target Price at $1.83
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30984899
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
August 25, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/08/25/cancer-vaccine-breakthrough-lifts-5-biotech-names-heres-whos-best-positioned/?utm_source=snapi
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacific-biosciences-of-california-inc-nasdaqpacb-given-average-recommendation-of-reduce-by-analysts-2026-08-21/
Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $30,409.43 in Stock
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pacb-insider-buying-and-selling-2026-08-19/
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-pacific-biosciences-of-california-nasdaqpacb-insider-sells-26911-shares-of-stock-2026-08-18/
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacbio-cuts-outlook-as-sprq-nx-transition-slows-targets-2028-cash-flow-positivity-2026-08-16/
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pacific-biosciences-of-california-inc-pacb-shares-sold-by-renaissance-technologies-llc-2026-08-09/
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacific-biosciences-of-california-nasdaqpacb-cut-to-sell-at-wall-street-zen-2026-08-08/
PACB Q2 deep dive: Leadership transition and SPRQ-Nx rollout shape outlook
August 7, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/pacb-q2-deep-dive-leadership-transition-and-sprq-nx-rollout-shape-outlook/ar-AA29y5n0
Pacific Biosciences of California, Inc. annonce des changements de direction, effectifs au 5 août 2026
August 6, 2026  |  zonebourse.comZ
Why Pacific Biosciences of California, Inc.’s (PACB) Stock Is Down 6.54%
August 6, 2026  |  aaii.comA
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970348/pacbio-q2-earnings-meet-estimates-revenues-miss-2026-sales-view-cut?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970348
PacBio forecasts $155M-$165M 2026 revenue while shifting to a leaner structure and pushing SPRQ-Nx adoption
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4627269-pacbio-forecasts-155m-165m-2026-revenue-while-shifting-to-a-leaner-structure-and-pushing-sprq
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931383-pacific-biosciences-of-california-inc-pacb-q2-2026-earnings-call-transcript
Pacific Biosciences: It's Only Getting Worse
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931448-pacific-biosciences-q2-its-only-getting-worse-reiterate-sell
Pacific Biosciences of California Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacific-biosciences-of-california-q2-earnings-call-highlights-2026-08-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Codexis stock logo

Codexis NASDAQ:CDXS

$1.46 +0.04 (+2.82%)
As of 04:00 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$4.70 0.00 (0.00%)
As of 04:00 PM Eastern

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$6.95 0.00 (0.00%)
As of 03:58 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.35 +0.05 (+3.85%)
As of 04:00 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas